Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA files no records under this name; these are its 2 companies' records, each linked to the record.
As of Nov 22, 2026, FDA's public records list Mitsubishi Tanabe Pharma and its 2 subsidiaries with 8 510(k) clearances and 2 complete response letters. The most recent is a complete response letter dated Oct 21, 2025: Complete response letter, NDA 218317.
Group recordsLabelled by a language model (which subsidiaries belong to the group) from the firm's FDA names. It is not an FDA field.: 10, 3 entities
510(k) clearances: 8
Complete response letters: 2
Records by year
Drug approvals, 510(k) clearances, recalls and letters, 2024 to 2026 to date, Mitsubishi Tanabe Pharma and its 2 subsidiaries
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
120242024Records1
120252025Records1vs 2024+0
20262026 to dateRecords0
Latest records
Newest first across sources; each opens the record
7 trials since 2013, 1 ongoing, by the sponsor of the products; see every authorized trial
A phase 3b, multicenter, randomized, double-blind extension study to evaluate the continued efficacy and safety of oral…Feb 10, 2022 · Closed · Edaravone (MT-1186)
A phase 2a,randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MT-3921 in subjects…Feb 24, 2021 · Pending · MT-3921
A phase 3b, multicenter, randomized, double-blind study to evaluate efficacy and safety of oral edaravone administered…Dec 30, 2020 · Closed · Edaravone (MT-1186)
A phase 3, multi-center, open-label, safety extension study of oral edaravone administered over 96 weeks in subjects…Sep 23, 2020 · Ongoing · Edaravone (MT-1186)
A phase 2, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study to evaluate efficacy, safety,…Sep 11, 2020 · Closed · Dersimelagon (MT-7117)
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, safety, and…Jul 20, 2020 · Closed · Dersimelagon (MT-7117)
A phase 3, multi-center, open-label, safety study of oral edaravone administered over 48 weeks in subjects with…Dec 23, 2019 · Closed · Edaravone (MT-1186)
Payments to doctors (Open Payments)
What 4 reporting entities in this group reported paying US doctors and teaching hospitals each year, $44.3M of it for research; see every company
$8.9M20192019Paid$8.9M
$7.3M20202020Paid$7.3Mvs 2019−$1.6M
$9.4M20212021Paid$9.4Mvs 2020+$2.1M
$5.9M20222022Paid$5.9Mvs 2021−$3.5M
$5.7M20232023Paid$5.7Mvs 2022−$218K
$5.3M20242024Paid$5.3Mvs 2023−$406K
$3.9M20252025Paid$3.9Mvs 2024−$1.4M
Approvals in Japan (PMDA)
34 approvals since 2008, 7 of them new active ingredients, matched by the Japanese company's name; see all Japanese approvals
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.